Drug-Induced Hypophosphatemia: Current Insights.

Haralampos Milionis, Matilda Florentin, Moses Elisaf, Efstathia Megapanou, George Liamis

Journal: Drug safety 2020;43(3):197-210

PMID: 31776845

Abstract

Phosphate is actively involved in many important biochemical pathways, such as energy and nucleic acid metabolism, cellular signaling, and bone formation. Hypophosphatemia, defined as serum phosphate levels below 2.5 mg/dL (0.81 mmol/L), is frequently observed in the course of treatment with commonly used drugs, such as diuretics, bisphosphonates, antibiotics, insulin, and antacids. Furthermore, this undesired effect may complicate the use of several novel medications, including teriparatide, denosumab, parenteral iron, and antiviral and antineoplastic agents. This review addresses drug-associated hypophosphatemia, focusing on underlying mechanisms and the most recent knowledge on this topic, in order to increase the insight of clinicians, with reference to early diagnosis and appropriate management.

Address: Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.; Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece. [email protected].

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.